Bharat Biotech inks pact with Ocugen for development, sale of Covaxin in US2 min read . Updated: 02 Feb 2021, 10:00 PM IST
Ocugen will have the commercial rights to the vaccine candidate in the US and will be responsible to conduct clinical trial and get emergency use authorisation EUA from the US FDA
New Delhi: Bharat Biotech International Ltd on Tuesday announced that it has signed a pact with Ocugen Inc, allowing the US-based biopharmaceutical firm to co-develop, supply, and commercialize the Indian vaccine maker’s Covid-19 vaccine Covaxin in the US market.
Login to enjoy exclusive benefits!
- Unlocked premium articles
- Personalized news
- Market Watchlist
- Insightful Newsletters & more